Tiziana Martino - Q Linea Chief Medical Officer
| QLINEA Stock | SEK 1.09 0.03 2.68% |
Executive
Ms. Tiziana Di Martino was appointed Chief Medical Officer at QLinea AB effective as of July 2019. She has more than 16 years experience in clinical practice, research and medical affairs positions in the microbial diagnostic industry. Her latest position was Head of Clinical Development EMEA at Accelerate Diagnostics. Tiziana Di Martino is a Medical Doctor from Universita Cattolica del Sacro Cuore in Rome, has a Masters degree in Toxicology from the University of Surrey and also holds an MBA from London Business School. since 2019.
| Age | 47 |
| Tenure | 5 years |
| Professional Marks | MBA |
| Phone | 46 1 84 44 36 10 |
| Web | https://www.qlinea.com |
Q Linea Management Efficiency
The company has return on total asset (ROA) of (0.3953) % which means that it has lost $0.3953 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7175) %, meaning that it generated substantial loss on money invested by shareholders. Q Linea's management efficiency ratios could be used to measure how well Q Linea manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | EXECUTIVE Age | ||
| Richard Jameson | Camurus AB | 59 | |
| Helena Brandt | Bonesupport Holding AB | 58 | |
Management Performance
| Return On Equity | -0.72 | |||
| Return On Asset | -0.4 |
Q linea AB Leadership Team
Elected by the shareholders, the Q Linea's board of directors comprises two types of representatives: Q Linea inside directors who are chosen from within the company, and outside directors, selected externally and held independent of QLINEA. The board's role is to monitor Q Linea's management team and ensure that shareholders' interests are well served. Q Linea's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Q Linea's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anders Lundin, CFO Officer | ||
| Thomas Fritz, Chief Officer | ||
| Jonas Jarvius, CEO Pres | ||
| Tiziana Martino, Chief Medical Officer | ||
| Henrik Jacobsson, Chief Officer | ||
| Ulrika Stolpe, HR Mang | ||
| Mats Gullberg, Vice President Research Director |
QLINEA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Q Linea a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.72 | |||
| Return On Asset | -0.4 | |||
| Operating Margin | (13.93) % | |||
| Current Valuation | 287.15 M | |||
| Shares Outstanding | 29.21 M | |||
| Shares Owned By Insiders | 12.15 % | |||
| Shares Owned By Institutions | 74.76 % | |||
| Price To Book | 1.68 X | |||
| Price To Sales | 21.31 X | |||
| Revenue | 9.34 M |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in QLINEA Stock
Q Linea financial ratios help investors to determine whether QLINEA Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in QLINEA with respect to the benefits of owning Q Linea security.